文献速递心脑血管急症重症综合管理与镇静镇痛

低剂量阿司匹林与健康老年人卒中及颅内出血风险:一项随机临床试验的二次分析

Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2023-07-03
一句话结论健康老年人每日100 mg阿司匹林未显著降低缺血性卒中(HR 0.89;95%CI 0.71-1.11),但显著增加颅内出血(HR 1.38;95%CI 1.03-1.84)。

该研究为ASPREE随机双盲安慰剂对照试验的二次分析,纳入19114名无心血管症状的社区老年人,每日100 mg肠溶阿司匹林或安慰剂,中位随访4.7年。阿司匹林未显著降低缺血性卒中(HR 0.89;95%CI 0.71-1.11),但颅内出血显著增加(1.1% vs 0.8%;HR 1.38;95%CI 1.03-1.84)。亚型分析中硬膜下、硬膜外及蛛网膜下腔出血组合HR 1.45(95%CI 0.98-2.16),出血性卒中HR 1.33(95%CI 0.87-2.04),均未达统计学显著。作者认为该发现对头部创伤后易发生颅内出血的老年人可能特别相关。

要点

  • 健康老年人每日100 mg阿司匹林未显著降低缺血性卒中(HR 0.89;95%CI 0.71-1.11)。
  • 阿司匹林组颅内出血108例(1.1%)vs 安慰剂组79例(0.8%),HR 1.38(95%CI 1.03-1.84),差异有统计学意义。
  • 硬膜下、硬膜外及蛛网膜下腔出血组合:阿司匹林组59例(0.6%)vs 安慰剂组41例(0.4%),HR 1.45(95%CI 0.98-2.16),未达统计学显著。
  • 出血性卒中:阿司匹林组49例(0.5%)vs 安慰剂组37例(0.4%),HR 1.33(95%CI 0.87-2.04),未达统计学显著。
  • 作者认为该发现对头部创伤后易发生颅内出血的老年人可能特别相关。

适用人群与场景

  • 居住在澳大利亚或美国的社区老年人,无心血管症状,纳入ASPREE试验。
  • 共19114人(女性10782人,56.4%;中位年龄74岁,IQR 71.6-77.7岁),其中阿司匹林组9525人,安慰剂组9589人。
  • 招募时间为2010年至2014年,中位随访4.7年(IQR 3.6-5.7年)。

处置流程与药物剂量

  • 每日100 mg肠溶阿司匹林或匹配安慰剂。

研究设计与关键结果

  • 研究类型:ASPREE随机双盲安慰剂对照试验的二次分析,纳入19114名无心血管症状的社区老年人。
  • 干预与对照:每日100 mg肠溶阿司匹林 vs 匹配安慰剂。
  • 主要终点:缺血性卒中发生率无统计学显著降低(HR 0.89;95%CI 0.71-1.11)。
  • 关键次要终点:颅内出血阿司匹林组108例(1.1%)vs 安慰剂组79例(0.8%),HR 1.38(95%CI 1.03-1.84),差异有统计学意义。
  • 硬膜下、硬膜外及蛛网膜下腔出血组合:阿司匹林组59例(0.6%)vs 安慰剂组41例(0.4%),HR 1.45(95%CI 0.98-2.16),未达统计学显著。
  • 出血性卒中:阿司匹林组49例(0.5%)vs 安慰剂组37例(0.4%),HR 1.33(95%CI 0.87-2.04),未达统计学显著。

证据类型、等级与局限

  • 证据类型:随机双盲安慰剂对照试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该研究发现每日低剂量阿司匹林显著增加颅内出血但未显著降低缺血性卒中,对头部创伤后易发生颅内出血的老年人可能特别相关。

指南或共识出处

  • ASPREE(Aspirin in Reducing Events in the Elderly)试验,注册号ISRCTN83772183。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Low-dose aspirin has been widely used for primary and secondary prevention of stroke. The balance between potential reduction of ischemic stroke events and increased intracranial bleeding has not been established in older individuals.

OBJECTIVE: To establish the risks of ischemic stroke and intracranial bleeding among healthy older people receiving daily low-dose aspirin.

DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) randomized, double-blind, placebo-controlled trial of daily low-dose aspirin was conducted among community-dwelling people living in Australia or the US. Participants were older adults free of symptomatic cardiovascular disease. Recruitment took place between 2010 and 2014, and participants were followed up for a median (IQR) of 4.7 (3.6-5.7) years. This analysis was completed from August 2021 to March 2023.

INTERVENTIONS: Daily 100-mg enteric-coated aspirin or matching placebo.

MAIN OUTCOMES AND MEASURES: Stroke and stroke etiology were predetermined secondary outcomes and are presented with a focus on prevention of initial stroke or intracranial bleeding event. Outcomes were assessed by review of medical records.

RESULTS: Among 19 114 older adults (10 782 females [56.4%]; median [IQR] age, 74 [71.6-77.7] years), 9525 individuals received aspirin and 9589 individuals received placebo. Aspirin did not produce a statistically significant reduction in the incidence of ischemic stroke (hazard ratio [HR], 0.89; 95% CI, 0.71-1.11). However, a statistically significant increase in intracranial bleeding was observed among individuals assigned to aspirin (108 individuals [1.1%]) compared with those receiving placebo (79 individuals [0.8%]; HR, 1.38; 95% CI, 1.03-1.84). This occurred by an increase in a combination of subdural, extradural, and subarachnoid bleeding with aspirin compared with placebo (59 individuals [0.6%] vs 41 individuals [0.4%]; HR, 1.45; 95% CI, 0.98-2.16). Hemorrhagic stroke was recorded in 49 individuals (0.5%) assigned to aspirin compared with 37 individuals (0.4%) in the placebo group (HR, 1.33; 95% CI, 0.87-2.04).

CONCLUSIONS AND RELEVANCE: This study found a significant increase in intracranial bleeding with daily low-dose aspirin but no significant reduction of ischemic stroke. These findings may have particular relevance to older individuals prone to developing intracranial bleeding after head trauma.

TRIAL REGISTRATION: ISRCTN.org Identifier: ISRCTN83772183.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Cloud GC, Williamson JD, Thao LTP, et al. Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People: Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37494038. doi:10.1001/jamanetworkopen.2023.25803

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。